Presently, exploring potential blood‐based biomarkers has become a focal point in the lung cancer field,10 with these easily accessible and cost‐effective indicators poised to become the next widely used ICIs predictive biomarkers after PD‐L1. The gene discussed is CD274; the disease is lung carcinoma.